KL1333 is on its way to pivotal clinical study - Pivotal study planned for the second half of 2021
Continued progress in KL1333.
KL1333 approved for phase I clinical trial
Continued positive trend for NeuroSTAT® Business operations
New business model generates opportunities
Focus forward on R&D
Important outlicensing deal and increased focus on core operations
Increased interest in NeuroVives product portfolio with cyclophilin inhibitors and energy regulators